All In MedTech

Device Trial Radar · NCT06059963

A Prospective, Multi-center, Observational Study for Signal-C Test Evaluation

Last checked: Nov 20, 2026Latest source record: Nov 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

12,000

Planned (sponsor's estimate)

Start

Jan 18, 2024

Primary completion

Oct 30, 2026

Study completion Dec 1, 2026

Sponsor

Lead sponsor
Universal DiagnosticsNot on our public-company list
Sponsor type
Industry
First posted
Sep 29, 2023

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
Yes
Who can join
All sexes, from 45 years, up to 84 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

To evaluate the performance characteristics of Signal-C™ a plasma circulating free-DNA test, to detect colorectal cancer and advanced precancerous lesions (APL) in an average risk screening population for 45 and over.

Conditions

  • Colorectal Cancer
  • Advanced Adenocarcinoma

Interventions

  • Signal-C™Device

    Signal-C™ is a qualitative next generation sequencing-based in vitro diagnostic assay that uses targeted hybridization-based capture next-generation sequencing together with bioinformatics and machine learning algorithm for detection and combination of methylation and fragmentation associated DNA marker regions. Signal-C™ utilizes circulating cell-free DNA (cfDNA) isolated from plasma of peripheral whole blood collected via venipuncture in Streck Cell-Free DNA Blood Collection Tubes (BCTs).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary ObjectiveTime frame: 1 year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Gastroenterology Consultants of SW Virginia

    Raonoke, Virginia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.